Ensysce Biosciences, Inc. Cash Flow Statement
ENSC|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$8M
FY2025
Free Cash Flow
-$8M
FY2025
Capital Expenditures
$123,643
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Ensysce Biosciences, Inc. used $8M in operating cash flow and negative free cash flow of $8M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | -$8.0M | -$10.6M | -$24.2M | -$29.1M |
| Depreciation & Amortization | $6.5K | $0 | $0 | $151 |
| Operating Cash Flow | -$7.5M | -$10.8M | -$17.9M | -$8.2M |
| Capital Expenditures | $123.6K | - | - | - |
| Free Cash Flow | -$7.6M | - | - | - |
| FCF Margin | -146.4% | - | - | - |